January 14, 2023
3 min watch
Save
VIDEO: Orasis provides update on positive data for presbyopia drop
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Paul Smith of Orasis Pharmaceuticals discusses phase 3 data for the CSF-1 eye drop for presbyopia treatment following its new drug application submission to the FDA.
“We’re encouraged to report that CSF-1 does indeed hit its mark,” he said. “We are excited to be next in this new and emerging category.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Smith reports being the Chief Operating Officer of Orasis.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.